Opinion: Doing well by doing good could be a viable strategy for pharma

03/29/2012 | Philly.com (Philadelphia)

Sanofi's strategy in the insulin market might provide a blueprint for other drugmakers facing an unsustainable business model and lack of capital, writes Daniel Hoffman. The company's iBGStar glucose monitor connects to a smartphone, linking patients to their health care providers and positioning Sanofi as a comprehensive diabetes company. "At the least, the program represents an easily discernible effort to do well by doing good, and that's not a bad approach for pharma to take," Hoffman writes.

View Full Article in:

Philly.com (Philadelphia)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Paralegal
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC